28 C
Vientiane
Friday, June 27, 2025
spot_img
Home Blog Page 241

Great Place To Work® Announces Australia’s Best Workplaces™ in Technology List 2025

SYDNEY, May 8, 2025 /PRNewswire/ — Great Place To Work® Australia proudly announces its 2025 Best Workplaces™ in Technology List, honouring 55 of the nation’s most outstanding technology employers. Now in its third year, this prestigious list recognises organisations that lead with trust, purpose, and innovation, elevating employee experience and setting benchmarks for excellence in the tech industry.

Recognising Excellence in a Fast-Moving Sector

Technology is a thriving industry in Australia, with forecasts predicting it will contribute A$250 billion to the national economy by 2030. In 2023, the Minister for Skills and Training, the Hon Brendan O’Connor, noted that Australia’s tech workforce had grown 8% year-on-year, placing the country on track to achieve the national goal of 1.2 million technology-related jobs by 2030.

As one of the fastest-growing sectors, technology is crucial in driving employment. The 2025 Best Workplaces in Technology List highlights the organisations that are helping this growth by building workplaces based on trust, inclusivity and purpose.

The 2025 list is based on confidential employee feedback from 28,102 voices across Australia’s tech sector, rigorously evaluated through the Great Place To Work Trust Index™ survey. While the methodology remains unchanged, the stories of progress, empowerment, and resilience continue to evolve.

“The 2025 Best Workplaces in Technology list celebrates 55 companies that are not only great employers but powerful industry leaders,” said Rebecca Moulynox, General Manager, Great Place To Work Australia & New Zealand. “What sets these organisations apart is their ability to foster innovation through cultures of trust, purpose, and inclusion. In a highly competitive and fast-moving sector, these companies are proving that strong leadership and a great employee experience are key drivers of sustained performance and market advantage.”

Top Performers: Where Innovation Meets Impact

This year, CrowdStrike, which has demonstrated impressive technological advancements through innovations such as Charlotte AI, takes the top spot in the medium and large category. CrowdStrike excels in inclusive leadership, mental health initiatives, and community engagement; they build a culture where well-being is a priority.

Smokeball ranks among the top for its exceptional employee-centred practices, including a $1,000 wellness allowance, dedicated ‘reboot days’ and robust hybrid work flexibility. Their holistic well-being programmes have led to lower employee turnover and demonstrated high morale across the organisation.

Centorrino Technologies (CT) makes a notable debut with a strong people-first approach, carbon neutrality since 2019, and a bold goal to offset all historical emissions by 2025. Their inclusive workplace is grounded in empathy, empowerment, and community partnerships, like supporting EatUp.

What Makes These Workplaces Stand Out?

All companies on this year’s list share a foundation of high-trust workplace cultures. They invest in leadership, employee development, mental health, and purpose-driven strategies. From flexible work environments and structured recognition programs to community initiatives and sustainability goals, these companies exemplify what it means to lead through people.

Notable standouts include:

  • Atlassian, returning for the third year with its flexible Team Anywhere model and AI-powered collaboration tools.
  • Cisco, for cultivating a “Conscious Culture” that embraces inclusion, mental health, and environmental stewardship.
  • REA Group, with a 99% retention rate among new leaders and a deep commitment to mental wellbeing and cultural empowerment.
  • AirTrunk, which combines internal mobility and inclusive leadership with socially impactful initiatives funded by Sustainability Linked Loans.
  • Mantel Group, disrupting traditional hierarchies to empower teams with trust and autonomy.

Raising the Bar for Australia’s Tech Ecosystem

This year’s list doesn’t just recognise great companies but shows that in an era defined by rapid digital transformation and talent competition, workplace culture is not just a people priority but it’s essential for business success.

Early trends reinforce that employee-centric practices drive business performance, from better retention to stronger employer branding and innovation outcomes. As such, the 2025 Best Workplaces in Technology List serves as both a recognition and a call to action for the industry.

Explore the Full List

To view the complete list of Australia’s Best Workplaces in Technology 2025 and learn how your organisation can earn recognition next year, visit the Great Place To Work Australia website.

About Great Place To Work

Great Place To Work is the global authority on workplace culture. Our mission is to help every place become a great place to work for all. We give leaders and organisations the recognition and tools to create a consistently and overwhelmingly positive employee experience, fostering cultures that are proven to drive business, improve lives, and better society. Our recognition is the most coveted and respected in the world for elevating employer brands to attract the right people. Our proprietary methodology and platform enable organisations to truly capture, analyse, and understand the experience of all employees. Our groundbreaking research empowers organisations to build cultures that retain talent and unlock the potential of every employee. Our coaches, content, and community connect the boldest leaders, ideas, and innovations in employee experience. Since 1992, our Certification™, Best Workplaces Lists, and global benchmarks have become the industry standard, built on data from more than 100 million employees in 150 countries around the world.

Peikko Australia Showcasing Innovative Construction Solutions at Sydney Build Expo 2025

SYDNEY, May 8, 2025 /PRNewswire/ — Peikko Australia, a subsidiary of the Finnish global leading precast and cast-in-situ construction supplier Peikko Group, is participating in the 2025 Sydney Build Expo, Australia’s premier construction and infrastructure event. The expo is taking place on May 7–8, 2025, at the Sydney International Convention Centre (ICC), where Peikko Australia is showcasing its latest innovations in Bolted Connections Solutions, Flooring Solutions, and DELTABEAM® Slim Floor Structure.

Peikko Australia team with Business Finland Senior Advisor Birgit Tegethoff GAICD (the lady in the middle) at Sydney Build 2025.
Peikko Australia team with Business Finland Senior Advisor Birgit Tegethoff GAICD (the lady in the middle) at Sydney Build 2025.

The Sydney Build Expo, organized by Oliver Kinross, is the largest construction trade show in the Southern Hemisphere. It serves as a premier platform for contractors, architects, engineers, home builders, developers, government entities, and building professionals, attracting over 25,000 professionals and 600 exhibitors worldwide. This year’s edition focused on themes including digital construction, sustainability, and infrastructure resilience, which align with Peikko Australia’s mission to provide a faster, safer, and more sustainable way to build.

Peikko Australia is participating in the Sydney Build Expo for the second time this year. At Stand J10, the company is showcasing its innovative solutions, demonstrating the resilience of its flooring armour joints under heavy-duty operations and highlighting the innovative DELTABEAM® system. In response to questions from attendees, Peikko Australia’s sales and engineering teams are providing in-depth explanations and comprehensive answers. Peikko’s solutions not only highlight the company’s innovative technology but also address key industry challenges, including enhancing installation efficiency, reducing costs, ensuring structural safety, and promoting sustainability.

“Our participation underscores Peikko’s commitment to supporting Australia’s urban transformation with innovative, sustainable technologies,” said Wayne Saunders, Managing Director of Peikko Australia.  “We were excited to showcase our latest solutions and contribute to the growth and development of Australia’s construction industry.”

Peikko Australia has been actively contributing to Australia’s goal of achieving net-zero emissions by 2050. Leveraging its local manufacturing capabilities in Yatala, QLD, the company is ensuring high-quality products tailored to the Australian market. Peikko Australia has completed hundreds of projects, including landmarks like the Jewel Towers on the Gold Coast and Queen’s Wharf Project in Brisbane.

Through innovative solutions and a commitment to sustainable practices, Peikko has been reducing the environmental impact of construction. By participating in the Sydney Build Expo and engaging in open discussions, Peikko is sharing its knowledge and solutions to help create a more sustainable future for the industry. For more information, please visit www.peikko.com.au.

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

GALWAY, Ireland, May 8, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company’s fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025.

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025, to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com.

Within 24 hours of the broadcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investorrelations.medtronic.com.

Looking ahead to fiscal year 2026, Medtronic plans to report its first, second, third, and fourth quarter results on Tuesday, August 19, 2025, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively. For these events, confirmation and additional details will be provided closer to the specific event.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Erika Winkels
Public Relations
+1-763-526-8478

Ryan Weispfenning
Investor Relations
+1-763-505-4626

Nick Offerman and Megan Mullally Bring Unscripted and Unfiltered Chaos to Vivid Sydney

SYDNEY, May 8, 2025 /PRNewswire/ — Television icons Nick Offerman and Megan Mullally will appear on stage together for the first time in Australia at Vivid Sydney 2025, the Southern Hemisphere’s largest arts and culture festival.

Unscripted and Unfiltered with Nick Offerman and Megan Mullally. Image credit Emily Shur
Unscripted and Unfiltered with Nick Offerman and Megan Mullally. Image credit Emily Shur

The husband-and-wife comedy duo will present Unscripted & Unfiltered with Nick Offerman & Megan Mullally at the International Convention Centre Sydney on Saturday, 14 June, closing the festival’s 23-day celebration of creativity and innovation.

Known globally for their iconic roles as Ron Swanson in Parks and Recreation and Karen Walker in Will & Grace respectively, Offerman and Mullally will engage in a candid conversation moderated by Australian broadcaster Zan Rowe. The pair will discuss their individual careers, partnership, and activism work in the LGBTQIA+ community and environmental issues.

On the duo’s visit to the Harbour City, Nick Offerman said “Megan and I are powerfully chuffed to get back to town for Vivid Sydney but also to reprise our lovemaking session atop the Sydney Harbour Bridge. Once we have recharged those particular batteries, we’ll be thrilled to transfer our slatternly energies to the Vivid Sydney audience. Come for the anecdotes and the burlesque lust in our every turn of phrase, then get stretched out before you get home, because there’s gonna be some canoodlin'”.

Vivid Sydney Festival Director, Gill Minervini said, “We couldn’t let Vivid Sydney take place this year without treating visitors to a masterclass in comedy. Nick and Megan are one of the funniest couples alive, and this conversation is set to be equal parts unpredictable and hilarious. Bolstering Vivid Sydney 2025’s line-up alongside lifestyle icon Martha Stewart and the formidable Nigella Lawson, there really is something for everyone.”

Every episode of iconic series Will & Grace and Parks and Recreation is available to stream on Stan, Australia’s leading streaming service and Supporting Partner of Vivid Sydney 2025. 

Tickets go on sale on Friday, 9 May at 9:00 am AEST at vividsydney.com.

About Vivid Sydney

Vivid Sydney, the Southern Hemisphere’s leading multi-artform festival, transforms Sydney into a vibrant hub of creativity, innovation and community connection. Over 23 nights, light installations, music, ideas and food inspire global audiences and drive cultural exchange. The 2025 theme, ‘Dream’, sparks imagination and engagement, attracting visitors and fuelling economic growth. Proudly owned by Destination NSW, Vivid Sydney showcases NSW’s cultural vibrancy and positions it as a global leader in artistic innovation. 

 

Vivid Sydney. Image credit - Destination NSW
Vivid Sydney. Image credit – Destination NSW

Cutting ship emissions at the source: Alisha Fredriksson and Roujia Wen in top 10 innovators of the Young Inventors Prize 2025

  • Most decarbonisation efforts in the maritime sector currently focus on updating the fleet with new ships and on transitioning to green fuels, which leave the shipowners with few options to meet emissions targets
  • UK-based Alisha Fredriksson (Sweden/Canada) and Roujia Wen (China) founded Seabound, a startup that builds retrofittable carbon capture system that traps CO₂ from ship exhausts 
  • The team is among top ten innovators of the Young Inventors Prize, to be awarded by the European Patent Office (EPO) on 18 June 2025

MUNICH, May 8, 2025 /PRNewswire/ — According to the Organisation for Economic Co-operation and Development, global shipping is a major contributor to emissions, releasing over 800 million tonnes of CO₂ each year. The European Commission also reports that EU maritime transport alone exceeded 124 million tonnes in 2021, accounting for 3-4% of the bloc’s total CO₂ emissions. While alternative fuels and new ship designs offer long-term solutions, most existing vessels lack a feasible retrofit option for cutting CO₂ emissions to meet emissions targets. Alisha Fredriksson (30) and Roujia Wen (29) co-founded Seabound to develop a retrofittablecarbon capture system to help shipowners cut emissions without replacing their fleets. By capturing CO₂ into solid limestone rather than storing it as a liquid or gas, Seabound’s solution makes offloading and processing simple, eliminating the need for complex onboard CO₂ equipment or specialised portside infrastructure. Their invention has earned them a place among the ten global innovators, known as Tomorrow Shapers, for the Young Inventors Prize 2025, selected from over 450 candidates by an independent jury.

A modular solution for maritime decarbonisation

Most carbon capture systems require costly, energy-intensive systems for compressing and storing CO₂ onboard, but Seabound’s compact, container-based system captures CO₂ directly from a ship’s exhaust and binds it with a lime-based sorbent to form solid limestone pellets. This removes the need for pressurised CO₂ tanks and also streamlines portside logistics as the limestone can be offloaded in shipping containers as ordinary cargo.      

The Seabound system is designed to offer flexibility to shipowners – the modular units can be scaled up to match a ship’s emissions. The system operates efficiently, using exhaust heat to sustain the process while requiring only minimal energy for sensors and valves. The limestone can then be sold for use as building materials or post-processed nearby port to release CO₂, which can be used in other products (e.g., e-fuel production) or for sequestration, with the lime recycled for future capture. The technology also removes sulphur emissions, making it a dual-purpose scrubber that helps ships cut pollution without costly fleet replacements.

From concepts to sea trials

Fredriksson and Wen met at university and co-founded Seabound in 2021, driven by the need for a practical solution to maritime emissions. Fredriksson had worked with maritime e-fuels, where captured CO₂ was needed as a feedstock but was in short supply. Wen, with a background in applied mathematics and AI, helped design a modular carbon capture system that could be easily installed on existing ships.We bind the CO₂ in solid form using calcium-based materials, making storage as simple as carrying cargo. No specialised equipment, no extreme conditions, just a stable, scalable way to reduce emissions at sea,” explained Wen.

They iterated through multiple working prototypes in their London workshop before moving to full-scale trials at sea. According to Seabound, their system was tested on a commercial cargo ship and successfully captured CO₂ at 78% efficiency and sulphur emissions at 90% efficiency. “Shipping is one of the last sectors to decarbonise, as existing solutions are neither effective nor economically viable yet. Carbon capture was an emerging technology in other sectors, so we began brainstorming ways to make it work and we decided to take on the challenge together,” added Fredriksson.  

The Young Inventors Prize celebrates worldwide innovators 30 and under using technology to address global challenges posed by the United Nations Sustainable Development Goals (SDGs). Fredriksson and Wen’s invention supports SDG 13 (Climate Action) by providing a practical, scalable solution for reducing carbon emissions in the maritime industry.

The prizes of the 2025 edition will be announced during a ceremony livestreamed from Iceland on 18 June 2025. 

Find more information about the invention’s impact, the technology and the inventor’s story here.

About the Young Inventors Prize

Aimed at individuals 30 and under, the Young Inventors Prize showcases the transformative power of youth-driven solutions and recognises the remarkable young people paving the way to a more sustainable future. Established in 2022, trophies were first handed out during the European Inventor Award ceremony. From 2025 onwards, the Prize will move up a gear with its own dedicated event, held separately from the Award. Among the 10 Tomorrow Shapers selected for each edition, three will be awarded a special prize: World Builders, Community Healers, and Nature Guardians. In addition, a People’s Choice winner, voted by the public online, will be revealed. Each Tomorrow Shaper will receive EUR 5 000, the three special prize winners will each receive an extra EUR 15 000. The People’s Choice winner will be awarded an additional EUR 5 000. Read more on the Young Inventors Prize eligibility and selection criteria.

About the EPO

With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe. Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO’s centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 46 countries, covering a market of some 700 million people. The EPO is also the world’s leading authority in patent information and patent searching.

HD Hyundai and Persona AI Sign Agreement to Deploy Humanoid Welding Robots for Shipbuilding Automation

HD Hyundai spearheads Korea’s first welding humanoid initiative through partnership with global AI and robotics leaders.

  • HD Korea Shipbuilding & Offshore Engineering and HD Hyundai Robotics sign MOU with Persona AI and Vazil for humanoid development tailored to shipyard welding
  • Development and deployment of humanoid robots for precise welding to enhance production efficiency and safety
  • Prototype completion targeted for end of 2026, with field testing and commercialization commencing in 2027

HOUSTON and ULSAN, South Korea, May 8, 2025 /PRNewswire/ — HD Korea Shipbuilding & Offshore Engineering (HD KSOE) and HD Hyundai Robotics today announced the signing of a landmark Memorandum of Understanding (MOU) with Persona AI, a leader in embodied artificial intelligence, and robotics integration and manufacturing firm Vazil Company. The agreement, signed during a formal ceremony in Houston, Texas, initiates a joint program to create humanoid robots capable of performing complex welding tasks in shipyard environments.

This strategic partnership aims to usher in a new era of human-machine collaboration. The initiative will deliver prototype humanoids by the end of 2026, with field testing and full commercial deployment scheduled to begin in 2027.

Under the agreement, the four parties will collaborate to develop humanoids equipped with advanced AI and robotic systems capable of high-precision welding. The goal is to enhance productivity and improve workplace safety in shipyards.

Persona AI will lead the development of humanoid hardware and AI-based control and learning algorithms. Vazil Company will develop the welding tools and build the industrial testing environment. HD KSOE will support deployment in live shipyard settings and provide field engineering data. HD Hyundai Robotics will contribute welding-path AI training data and performance validation.

HD KSOE Senior Vice President Mr. Dong-ju Lee stated, “Welding humanoids will not only boost productivity but also significantly reduce the burden on workers and greatly enhance safety. By developing robots optimized for shipyard tasks, we aim to set a new paradigm in shipbuilding automation. Our goal is a smart shipyard where humans and intelligent robots collaborate seamlessly.”

Persona AI CEO Nicolaus Radford added, “As heavy industry faces growing labor constraints—especially in high-risk trades like welding—the need for rugged, autonomous humanoid robots is more urgent than ever. This partnership with HD Hyundai and Vazil is more than symbolic—deploying to the shipyard is one of the largest real-world proving grounds for Persona’s tough, humanoid robots.

HD Hyundai Robotics Vice President Mr. Young-hoon Song stated, ” Unlike conventional robots that focus solely on repetitive tasks, these robots must be able to observe, reason, and make decisions. By leveraging HD Hyundai Robotics’ extensive experience in robotic automated welding and engineering, we aim to develop an innovative humanoid welding solution.”

Vazil Company CTO Sungwon Kim commented, “By developing humanoids capable of precision welding, we will elevate shipyard automation to the next level. We look forward to our manufacturing partnership with Persona AI to help them build and deploy to the Korean markets. This partnership marks a significant milestone in a global industrial robotics collaboration.”

About HD Hyundai KSOE
HD Korea Shipbuilding & Offshore Engineering (KSOE) is a global leader in shipbuilding and advanced marine engineering. It oversees HD Hyundai Heavy Industries, HD Hyundai Mipo, and HD Hyundai Samho. Learn more at hdksoe.co.kr.

About Persona AI
Persona AI develops embodied AI systems capable of working alongside humans in dangerous, high-impact environments. The company brings decades of experience in space- and ocean-grade robotics to real-world labor challenges. Learn more at http://www.personainc.ai 

About HD Hyundai Robotics Corporation
HD Hyundai Robotics Corporation is a global leader in industrial automation and smart manufacturing solutions. A subsidiary of HD Hyundai, the company specializes in robotic systems for welding, assembly, and logistics across sectors including shipbuilding, energy, and heavy industry. hd-hyundairobotics.com

About Vazil Company
Vazil develops advanced automation, AI, and robotics solutions for industrial clients in South Korea and globally. Visit vazilcompany.com for more information.

Pictured from left: Mingyu Kim (Research Engineer) VAZIL Company, Jerry Pratt (CTO) Persona AI, Inc, Jide Akinyode (COO) Persona AI, Inc, Sungwon Kim (CTO) VAZIL Company, Nicolaus Radford (CEO) Persona AI, Inc, Dongju Lee (Senior Vice President) HD KSOE, Younghoon Song (Vice President) HD Hyundai Robotics, Won Jun Yun (Principal Research Engineer) HD KSOE.
Pictured from left: Mingyu Kim (Research Engineer) VAZIL Company, Jerry Pratt (CTO) Persona AI, Inc, Jide Akinyode (COO) Persona AI, Inc, Sungwon Kim (CTO) VAZIL Company, Nicolaus Radford (CEO) Persona AI, Inc, Dongju Lee (Senior Vice President) HD KSOE, Younghoon Song (Vice President) HD Hyundai Robotics, Won Jun Yun (Principal Research Engineer) HD KSOE.

 

Redefining Utility-Scale Storage: Envision Unveils EN 8 Pro at Smarter E Europe 2025

MUNICH, May 8, 2025 /PRNewswire/ — Envision Energy, a global leader in green technology , today announced the launch of its next-generation EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System at Smarter E Europe 2025. Designed to accelerate the transition to an intelligent, resilient, and net-zero energy future, the EN 8 Pro sets a new benchmark in safety, performance, cost-efficiency, and environmental adaptability. Featuring a high energy density design that delivers over 8MWh high capacity, it combines advanced fire protection, intelligent thermal management, and reduced Levelized Cost of Energy (LCOE), making it an ideal solution for large-scale renewable integration and utility-scale energy storage.

Envision Energy Unveils EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System at Smarter E Europe 2025
Envision Energy Unveils EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System at Smarter E Europe 2025

Prevention-First Strategy for Ultra-Safety

Envision’s “Prevention First”  fire safety strategy is fully embodied in the EN 8 Pro.

  • Multi-layer defence combining three levels of fire suppression with active and passive deflagration control for full fire protection from cell to system level.
  • Patented Triple-Fuse Cell Technology -electrical, gas, and solid-state fuses greatly reduces cell-level thermal runaway risk, by interrupting electrical pathways, relieving pressure, and blocking ion transport.
  • Early Fault Detection: AI-IoT diagnostics predict early failure warnings and continuous health insights for proactive intervention.
  • Fully compliant with NFPA 855 and NFPA 68/69, the system delivers industry-leading protection under extreme conditions.

Lower LCOE and  HigherPerformance

  • 26 % smaller footprint (4-hour system) and 12 % lower auxiliary power drive down LCOE.
  • Quick-connect interface allows pack replacement in under one hour, minimising downtime.
  • 700 Ah-plus cells provide > 8 MWh capacity with higher energy density and long service life.
  • Precision SoC algorithms and millisecond-level data acquisition optimize energy management in real time.

Exceptional Environmental Adaptability

With IP55 protection, C5 anti-corrosion ratings, and low-noise technology — achieving 20dB quieter than typical industry standards, the EN 8 Pro thrives in harsh climates, sound-sensitive areas, urban centres, and industrial zones alike.

“In the race to net-zero, energy storage must be safer, smarter, and more efficient,” said Kevin Huang, Senior Vice President and President of Energy Storage Product Line at Envision Energy, “The EN 8 Pro is not just a product launch — it’s a leap forward in how we think about building a decarbonized, AI-driven energy system at scale. With industry-leading safety innovations, record energy density, and exceptional environmental resilience, the EN 8 Pro addresses the real challenges of the global energy transition. We are proud to debut it at Smarter E Europe 2025, a global stage where technology and action meet to accelerate a sustainable future.”

The EN 8 Pro  is poised to support utility-scale renewable integration, grid stabilization, and energy transition projects worldwide.

End 

 

 

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer[1].

TLX400 (177Lu-DOTAGA.Glu.(FAPi)2) has been in-licensed by Telix as part of a portfolio of next-generation therapeutic and diagnostic (“theranostic”) radiopharmaceutical candidates[2]. TLX400 has potential clinical utility in several oncology indications. The publication provides further validation of the safety profile and potential efficacy of Telix’s lead FAP therapeutic candidate.

In this peer-reviewed manuscript, Dr. Sanjana Ballal and colleagues report results from 73 heavily pre-treated patients with RAI-R follicular thyroid carcinoma[3]. The authors conclude that TLX400 therapy demonstrated a promising safety profile and efficacy in aggressive, RAI-R thyroid cancer, achieving a median progression-free survival (PFS) and overall survival (OS) of 29 and 32 months, respectively, with a manageable adverse event profile.

The therapeutic approach to radioiodine-refractory thyroid cancer has advanced with tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib, supported by the DECISION trial[4] and SELECT study[5] results. However, their potential risks, including significant side effects, require careful management, particularly in patients with comorbidities such as cardiac issues, hypertension, stroke, and kidney dysfunction, who may not be optimal candidates for TKI therapy. Lutetium-177 (177Lu)-FAP inhibitor therapy marks a significant advancement in thyroid cancer theranostics, where FAP in cancer-associated fibroblasts (CAFs) influences the tumor microenvironment (TME), angiogenesis, and chemotherapy resistance. CAFs interact with cancer cells, fostering tumor growth and aggressiveness, highlighting their significance as therapeutic targets and in elucidating tumor progression mechanisms.

Dr. Sanjana Ballal, Senior Researcher at the All India Institute of Medical Sciences (AIIMS, New Delhi), investigator and lead author, commented, “This preliminary study highlights the promising safety profile and efficacy of TLX400 therapy in aggressive radioiodine-resistant thyroid cancer, including refractory cases. Notably, in the cohort of patients with reported efficacy, the treatment demonstrated median OS and PFS durations of 32 and 29 months, with a promising 50% partial response rate. Adverse events, primarily hematotoxicity – typical of radiopharmaceuticals – were manageable, emphasizing potential as a promising treatment option for this challenging patient population.”

TLX400 is differentiated by a novel structure that drives prolonged tumor retention while minimizing off-target uptake, designed to overcome the limitations seen with first-generation FAP-targeting compounds. These candidates have extensive pre-clinical and clinical data covering a range of tumors[6]. Telix is exploring the clinical utility of the FAP portfolio across a range of solid tumors, including bladder cancer.

Dr. David N. Cade, Group Chief Medical Officer, Telix, added, “We are highly encouraged by these data for TLX400, which compare favourably to TKIs – the standard of care treatment in patients with thyroid cancer – for OS and PFS. This provides further validation of the safety profile and efficacy potential enabled by the novel design of these FAP-targeting therapeutic candidates.”

The Thyroid publication is available online at: https://www.liebertpub.com/doi/10.1089/thy.2024.0229

[1] Ballal et al. Thyroid. 2025. https://www.liebertpub.com/doi/10.1089/thy.2024.0229 

[2] Telix ASX disclosure 12 March 2025.

[3] The data were collected as part of a compassionate use program covered by an overarching protocol, approved by the institutional ethics board.

[4] Brose et al. Lancet. 2014.

[5] Schlumberger et al. N Engl J Med. 2015.

[6] See Telix investor presentation lodged with the ASX on 19 November 2024.

About  Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

TLX400 has not received a marketing authorization in any jurisdiction.

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com  

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.